August 2003 Cover
|
 |
Bristol-Myers Squibb Co. won the backing of a government advisory panel for atazanavir, a new HIV treatment, after getting favorable comments from reviewers. US Food and Drug Administration analyses "support the applicant's findings" on safety and efficacy, agency staff said.
Atazanavir's once-daily dosing makes it more convenient than rival protease inhibitors.
Bristol-Myers' research found atazanavir less likely to change the level of some fats circulating in patients' blood-- a complication of some therapies that often forces patients to take other drugs to lower their risk of heart disease.
Editor's Note: from the Associated Press
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
